Intranasal Esketamine + CBT: a 6 months follow-up of a resistant depression complicated case

Intranasal Esketamine + CBT: a 6 months follow-up of a resistant depression complicated case

Introduction TRD is a highly disabling condition, often responsible for chronic clinical course, high number of relapses and elevated suicide risk. Intranasal esketamine is currently the only available pharmacological therapy specifically indicated for TRD, as add-on therapy to antidepressant treat...

Full description

Bibliographic Details
Main Authors:	V. Martiadis, F. Raffone, R. Cerlino, F. Mistico, M. Russo
Format:	Article
Language:	English
Published:	Cambridge University Press 2022-06-01
Series:	European Psychiatry
Subjects:	esketamine treatment resistant depression CBT Quality of Life
Online Access:	https://www.cambridge.org/core/product/identifier/S0924933822014316/type/journal_article

Similar Items

Intranasal esketamine + Intensive CBT: a 12 months follow-up of two complicated cases of Treatment Resistant Depression at high suicidal risk
by: V. Martiadis, et al.
Published: (2023-03-01)

The role of intranasal esketamine in treatment-resistant depression
by: A. Fraga, et al.
Published: (2021-04-01)

Clinical stability after compassionate use of intranasal esketamine in treatment-resistant depression
by: D. Hernandez Huerta, et al.
Published: (2022-06-01)

Case report: Intranasal esketamine for severe major depressive disorder with psychotic features
by: Maximilian Carter, et al.
Published: (2022-07-01)

Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders
by: Miriam Olivola, et al.
Published: (2022-02-01)

The Efficacy and Safety of Intranasal Formulations of Ketamine and Esketamine for the Treatment of Major Depressive Disorder: A Systematic Review
by: Ludivine Boudieu, et al.
Published: (2023-12-01)

Long-Term Efficacy of Intranasal Esketamine in Treatment-Resistant Major Depression: A Systematic Review
by: Enrico Capuzzi, et al.
Published: (2021-08-01)

Esketamine and Psilocybin—The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review
by: Dominika Psiuk, et al.
Published: (2022-09-01)

Case report: Intramuscular ketamine or intranasal esketamine as a treatment in four patients with major depressive disorder and comorbid anorexia nervosa
by: Johanna Louise Keeler, et al.
Published: (2023-05-01)

How effective are ketamine or esketamine in treatment-resistant depression?
by: N. Veluri, et al.
Published: (2021-04-01)

Esketamine, a new treatment for resistant depression: a systematic review of the literature
by: Mercedes Valtueña García, et al.
Published: (2021-07-01)

Clinical efficacy and tolerability of Esketamine: a case series
by: C. Passani, et al.
Published: (2022-06-01)

Intranasal esketamine use in bipolar disorder: A case report
by: Courtney Skriptshak, PharmD, et al.
Published: (2021-07-01)

Possible Use of Minocycline in Adjunction to Intranasal Esketamine for the Management of Difficult to Treat Depression following Extensive Pharmacogenomic Testing: Two Case Reports
by: Matteo Marcatili, et al.
Published: (2022-09-01)

Treating with esketamine nasal, will increase blood pressure?
by: V. Rosello-Molina, et al.
Published: (2021-04-01)

Impact of Repeated Doses of Subcutaneous Esketamine on Acute Dissociative Symptoms in Treatment-Resistant Depression
by: Lorena Catarina Del Sant, et al.
Published: (2022-12-01)

Heterogeneous trajectory of depressive symptoms after repeated subcutaneous esketamine injections
by: Matheus Ghossain Barbosa, et al.
Published: (2021-01-01)

Early real-life evaluation of the efficacy of esketamine in resistant depressive disorder
by: S. Faisant, et al.
Published: (2022-06-01)

Montgomery‐Åsberg Depression Rating Scale factors in treatment‐resistant depression at onset of treatment: Derivation, replication, and change over time during treatment with esketamine
by: Stephane Borentain, et al.
Published: (2022-12-01)

Esketamine pretreatment during cesarean section reduced the incidence of postpartum depression: a randomized controlled trail
by: Shixia Xu, et al.
Published: (2024-01-01)

Effect of Sleep Disturbance on Efficacy of Esketamine in Treatment-Resistant Depression: Findings from Randomized Controlled Trials
by: Borentain S, et al.
Published: (2021-11-01)

A randomized double-blind trial of intranasal dexmedetomidine versus intranasal esketamine for procedural sedation and analgesia in young children
by: Anna Nikula, et al.
Published: (2024-03-01)

Effects of intranasal (S)-ketamine on Veterans with co-morbid treatment-resistant depression and PTSD: A retrospective case series
by: Hewa Artin, et al.
Published: (2022-06-01)

Efficacy and Safety of Esketamine Combined with Antidepressants for Treatment-Resistant Depression: A Meta-Analysis
by: Liu P, et al.
Published: (2022-12-01)

Effect of postoperative application of esketamine on postoperative depression and postoperative analgesia in patients undergoing pancreatoduodenectomy: a randomized controlled trial protocol
by: Kaili Yu, et al.
Published: (2023-08-01)

Esketamine in patient with treatment resistant depression: Outcome of the temporary authorization for use programme in France
by: E. Gaudre Wattinne, et al.
Published: (2021-04-01)

Repeated, low-dose oral esketamine in patients with treatment-resistant depression: pilot study
by: Sanne Y. Smith-Apeldoorn, et al.
Published: (2022-01-01)

Short-term cognitive effects of repeated-dose esketamine in adolescents with major depressive disorder and suicidal ideation: a randomized controlled trial
by: Xiaofeng Lan, et al.
Published: (2023-09-01)

The cognitive effects of esketamine: what do we know so far?
by: M. Barbosa, et al.
Published: (2022-06-01)

Effect of esketamine on postoperative depressive symptoms in patients undergoing thoracoscopic lung cancer surgery: A randomized controlled trial
by: Shu-lin Gan, et al.
Published: (2023-03-01)

The efficacy and safety of esketamine in the treatment of major depressive disorder with suicidal ideation: study protocol for a randomized controlled trial
by: Haiyan Liu, et al.
Published: (2022-11-01)

Efficacy and safety of ketamine and esketamine for unipolar and bipolar depression: an overview of systematic reviews with meta-analysis
by: Alessandro Rodolico, et al.
Published: (2024-02-01)

A comparison between patients who suffer from major depression and are treated with Esketamine – one group participates in group therapy and the other one does not
by: H. Yaniv, et al.
Published: (2022-06-01)

Case report: Effectiveness of brexpiprazole and esketamine/ketamine combination: A novel therapeutic strategy in five cases of treatment-resistant depression
by: Lai Fong Chan, et al.
Published: (2022-07-01)

Repeated oral esketamine in patients with treatment resistant depression and comorbid posttraumatic stress disorder
by: J.K.E. Veraart, et al.
Published: (2023-05-01)

Global Trends and Hotspots in Esketamine Research: A Bibliometric Analysis of Past and Estimation of Future Trends
by: Li X, et al.
Published: (2022-04-01)

Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality
by: Dong-Jing Fu, et al.
Published: (2023-08-01)

Repeated intravenous esketamine treatment in patients with ECT-resistant major depressive disorder
by: A. Safai Pour, et al.
Published: (2022-12-01)

Investigating the antidepressant effects of CBT-I in those with major depressive and insomnia disorders
by: Parky H. Lau, et al.
Published: (2022-07-01)

The drug liking and craving questionnaire (DLCQ) to evaluate addiction risk for ketamine and esketamine
by: Jay Wang, et al.
Published: (2022-03-01)